| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.NANO.2016.04.013 |
| P8608 | Fatcat ID | release_ebv4weu6pnf7tbsnyifrqif5e4 |
| P932 | PMC publication ID | 5115211 |
| P698 | PubMed publication ID | 27151564 |
| P2093 | author name string | Xiuling Lu | |
| Qiang Fu | |||
| Derek Hargrove | |||
| P2860 | cites work | Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer | Q50512108 |
| Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. | Q51301047 | ||
| Communication between peritoneal cavity and mediastinal lymph nodes demonstrated by Tc-99m albumin nanocolloid intraperitoneal injection. | Q51662064 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Peritoneal absorption of macromolecules studied by quantitative autoradiography | Q67276014 | ||
| Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study | Q67520718 | ||
| Selective delivery of 5-fluorouracil (5-FU) to i.p. tissues using 5-FU microspheres in rats | Q73162168 | ||
| Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest | Q73358276 | ||
| Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study | Q74257275 | ||
| Effect of maceligan on the systemic exposure of paclitaxel: in vitro and in vivo evaluation | Q84521048 | ||
| A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies | Q33422212 | ||
| Multiscale tumor spatiokinetic model for intraperitoneal therapy | Q33574144 | ||
| Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals | Q34188389 | ||
| Intraperitoneal therapy for peritoneal cancer | Q34789701 | ||
| Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy | Q37224751 | ||
| Recent advances in biocompatible nanocarriers for delivery of chemotherapeutic cargoes towards cancer therapy | Q38204933 | ||
| Molecular and supramolecular switches on mesoporous silica nanoparticles | Q38437008 | ||
| Gated Materials for On-Command Release of Guest Molecules | Q38686807 | ||
| Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models | Q38821043 | ||
| Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer | Q39253063 | ||
| Successfully tailoring the pore size of mesoporous silica nanoparticles: exploitation of delivery systems for poorly water-soluble drugs | Q39256920 | ||
| Pharmacological effects of 5-fluorouracil microspheres on peritoneal carcinomatosis in animals | Q40000525 | ||
| Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation | Q40157398 | ||
| In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes | Q44044313 | ||
| The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes | Q45406467 | ||
| Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration | Q47220609 | ||
| P433 | issue | 7 | |
| P921 | main subject | paclitaxel | Q423762 |
| P304 | page(s) | 1951-1959 | |
| P577 | publication date | 2016-05-02 | |
| P1433 | published in | Nanomedicine: Nanotechnology, Biology and Medicine | Q6964073 |
| P1476 | title | Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery | |
| P478 | volume | 12 |
| Q64084253 | Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells |
| Q47274086 | Enhanced efficacy of curcumin with phosphatidylserine-decorated nanoparticles in the treatment of hepatic fibrosis |
| Q57372130 | Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances |
| Q47165034 | Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. |
| Q92617881 | Pharmacokinetic problems in peritoneal drug administration: an update after 20 years |
| Q55114331 | Synthesis of Controlled-Size Silica Nanoparticles from Sodium Metasilicate and the Effect of the Addition of PEG in the Size Distribution. |
Search more.